Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma
Case Reports in Oncological Medicine · 16.06.2021 · 2021 · 1-6
DOI: 10.1155/2021/5532258 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncological Medicine, erschienen am 16.06.2021. Verfasst von Hideaki Sabe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Angiomatoid fibrous histiocytoma (AFH) is a rare soft tissue tumor that rarely metastasizes but lacks effective systemic therapy once it propagates. In some reports, high interleukin-6 (IL-6) production promotes tumor growth by autocrine stimulation and tocilizumab, an IL-6 receptor antagonist, can control AFH growth. Here, we present a case report on a patient with local recurrence and distant lymph node metastasis of AFH treated with tocilizumab. As a result, the inhibition of the IL-6 signaling pathway controlled paraneoplastic inflammatory syndrome (PIS); however, the local recurrent tumor progressed. This case implied that IL-6 is not necessarily the cause of tumor growth in AFH. Therefore, physicians should bear in mind that watchful observation is needed whether tocilizumab can control tumor progression despite the amelioration of PIS associated with the attenuated effect of IL-6 on AFH.
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
- Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
- Department of Rehabilitation, Osaka International Cancer Institute, Osaka 541-8567, Japan.
ORCID-Profile: Hironari Tamiya
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Sabe, H., Inoue, A., Nagata, S., Imura, Y., Wakamatsu, T., Takenaka, S., & Tamiya, H. (2021). Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma. Case Reports in Oncological Medicine, 2021, 1-6. https://doi.org/10.1155/2021/5532258
Vancouver
Sabe H, Inoue A, Nagata S, Imura Y, Wakamatsu T, Takenaka S, et al. Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma. Case Reports in Oncological Medicine. 2021;2021:1-6. doi:10.1155/2021/5532258
BibTeX
@article{Sabe2021,
author = {Sabe, Hideaki and Inoue, Akitomo and Nagata, Shigenori and Imura, Yoshinori and Wakamatsu, Toru and Takenaka, Satoshi and Tamiya, Hironari},
title = {Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma},
journal = {Case Reports in Oncological Medicine},
year = {2021},
volume = {2021},
pages = {1--6},
doi = {10.1155/2021/5532258}
}
EUVIMED